Eye­Point sells re­main­ing rights to eye im­plant, piv­ots to tack­le an­ti-VEG­Fs

Eye­Point is sell­ing off the re­main­ing glob­al rights to its in­trav­it­re­al im­plant Yu­tiq to Al­imera, an­oth­er eye-fo­cused biotech, for $82.5 mil­lion.

Eye­Point Phar­ma­ceu­ti­cals

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER